Clinical Trial Update: Enhancing Prolonged Exposure With Cannabidiol to Treat Posttraumatic Stress Disorder [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating cannabidiol as an adjunct to prolonged exposure therapy for posttraumatic stress disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Posttraumatic Stress Disorder

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Posttraumatic Stress Disorder, Stress Disorders, Post-Traumatic | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-10